Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells

Anti‐PD‐1/PD‐L1 immunotherapy could offer an alternative to traditional chemo‐ and/or radiotherapy to treat pediatric cancer patients. To unveil the potential benefit of this new therapeutic approach, the prevalence of PD‐L1 and other relevant immune markers using quantitative digital image analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Manuel A, Triltsch, Nicolas, Leis, Simon, Kanchev, Ivan, Tan, Tze Heng, Van Peel, Benjamine, Van Kerckhoven, Marian, Deschoolmeester, Vanessa, Zimmermann, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164376/
https://www.ncbi.nlm.nih.gov/pubmed/31922656
http://dx.doi.org/10.1002/cjp2.152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164376/
https://www.ncbi.nlm.nih.gov/pubmed/31922656
http://dx.doi.org/10.1002/cjp2.152

Ejemplares similares